ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
shemara
|
17 |
4.0K |
4 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
17
|
4.0K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
21K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
21K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
21K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
21K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
21K |
6 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
21K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
698 |
281K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
698
|
281K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
428 |
150K |
5 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
428
|
150K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: US patent allowed for CHM 0201 (CORE-NK) technology
|
|
shemara
|
15 |
5.7K |
5 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
15
|
5.7K
|
5
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Final Director's Interest Notice MB
|
|
shemara
|
16 |
5.9K |
1 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
16
|
5.9K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
428 |
150K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
428
|
150K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
shemara
|
68 |
23K |
9 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
68
|
23K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
shemara
|
10 |
4.4K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
4.4K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
shemara
|
10 |
4.4K |
6 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
4.4K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
698 |
281K |
2 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
698
|
281K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
shemara
|
34 |
10K |
2 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
34
|
10K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Entitlement Offer
|
|
shemara
|
44 |
12K |
2 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
44
|
12K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Results of Annual General Meeting
|
|
shemara
|
12 |
3.9K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
12
|
3.9K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM secures up to A$12.6m through SPP and placements
|
|
shemara
|
18 |
8.4K |
3 |
24/06/23 |
24/06/23 |
ASX - By Stock
|
18
|
8.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Share purchase plan completed
|
|
shemara
|
11 |
2.4K |
2 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
11
|
2.4K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
428 |
150K |
6 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
428
|
150K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
shemara
|
138 |
45K |
3 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
138
|
45K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Viral Vector Manufacturing for Phase 1 trial
|
|
shemara
|
16 |
6.4K |
2 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
16
|
6.4K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM to host CAR T Cell Therapies Educational Webinar
|
|
shemara
|
13 |
5.3K |
3 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
5.3K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
698 |
281K |
4 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
698
|
281K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
shemara
|
138 |
45K |
2 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
138
|
45K
|
2
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
shemara
|
32K |
15M |
0 |
10/03/23 |
10/03/23 |
Charts
|
32K
|
15M
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE
|
|
shemara
|
35 |
11K |
3 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
35
|
11K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Appendix 4E and Preliminary Final Report
|
|
shemara
|
23 |
8.5K |
2 |
05/09/22 |
05/09/22 |
ASX - By Stock
|
23
|
8.5K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Licenses viral vector technology from Penn for CDH17
|
|
shemara
|
30 |
11K |
2 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
30
|
11K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: A$30 million Equity Placement Agreement with L1 Capital
|
|
shemara
|
43 |
16K |
3 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
43
|
16K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: A$30 million Equity Placement Agreement with L1 Capital
|
|
shemara
|
43 |
16K |
4 |
11/06/22 |
11/06/22 |
ASX - By Stock
|
43
|
16K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
3 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
380
|
176K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
698 |
281K |
4 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
698
|
281K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.0K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.0K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.0K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.0K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
380
|
176K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.0K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.0K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.0K |
0 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.0K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.0K |
1 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
11
|
4.0K
|
1
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
shemara
|
20K |
16M |
2 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
20K
|
16M
|
2
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
1 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
380
|
176K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
2 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
380
|
176K
|
2
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Change of Director's Interest Notice - RC
|
|
shemara
|
2 |
1.2K |
2 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
2
|
1.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
My analysis and intrinsic value of CHM March 2022
|
|
shemara
|
13 |
5.3K |
8 |
27/03/22 |
27/03/22 |
ASX - By Stock
|
13
|
5.3K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER
|
|
shemara
|
19 |
8.6K |
6 |
23/03/22 |
23/03/22 |
ASX - By Stock
|
19
|
8.6K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Trading Halt
|
|
shemara
|
11 |
3.9K |
3 |
23/03/22 |
23/03/22 |
ASX - By Stock
|
11
|
3.9K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
4 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
380
|
176K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
2 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
380
|
176K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
176K |
4 |
27/02/22 |
27/02/22 |
ASX - By Stock
|
380
|
176K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $18.1 million
|
|
shemara
|
78 |
25K |
3 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
78
|
25K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $18.1 million
|
|
shemara
|
78 |
25K |
5 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
78
|
25K
|
5
|
|